Post-Market Performance Follow-up (PMPF) under IVDR 2017/746

PMPF Made Simple: Proving Performance After Launch
Post-Market Performance Follow-up (PMPF) is how you keep proving your IVD still performs properly after it’s on the market. Under IVDR, performance evaluation doesn’t “finish” at CE marking manufacturers must keep collecting real-world evidence to confirm the test remains accurate, reliable, and clinically useful throughout its life. PMPF sits inside the wider PMS system, but it focuses specifically on performance (analytical + clinical) rather than general complaints alone. IVDR makes PMPF a clear requirement: Article 56(6) says the performance evaluation must be updated using data from the PMPF plan and PMS plan, and Annex XIII Part B explains what must be in the PMPF Plan and PMPF Evaluation Report. In plain terms, regulators want an auditable approach showing you have a planned method to track performance and update your documents when new data appears. A PMPF Plan should explain what you will monitor, how you will collect data, and when you will review it. Typical objectives are to confirm real-world sensitivity/specificity and reproducibility, detect new issues (e.g., false results, matrix effects, reagent stability problems), and check that the benefit–risk balance and IFU claims are still valid as science and clinical practice change. The PMPF Evaluation Report then summarizes and interprets the collected evidence and triggers updates to the Performance Evaluation Report (PER), risk management, labeling/IFU, or CAPA when needed. PMS vs PMPF is easy to remember: PMS = broad safety/quality monitoring (often reactive), while PMPF = planned, proactive performance confirmation using structured sources like studies, registries, literature, or real-world datasets. PMPF can sometimes be justified as “not needed” for well-established devices, but this must be clearly documented and strongly supported because notified bodies usually expect a convincing rationale, not a simple statement.

PMPF Made Simple: Proving Performance After Launch

Post-Market Performance Follow-up (PMPF) is how you keep proving your IVD still performs properly after it’s on the market. Under IVDR, performance evaluation doesn’t “finish” at CE marking manufacturers must keep collecting real-world evidence to confirm the test remains accurate, reliable, and clinically useful throughout its life. PMPF sits inside the wider PMS system, but it focuses specifically on performance (analytical + clinical) rather than general complaints alone.

IVDR makes PMPF a clear requirement: Article 56(6) says the performance evaluation must be updated using data from the PMPF plan and PMS plan, and Annex XIII Part B explains what must be in the PMPF Plan and PMPF Evaluation Report. In plain terms, regulators want an auditable approach showing you have a planned method to track performance and update your documents when new data appears.

A PMPF Plan should explain what you will monitor, how you will collect data, and when you will review it. Typical objectives are to confirm real-world sensitivity/specificity and reproducibility, detect new issues (e.g., false results, matrix effects, reagent stability problems), and check that the benefit–risk balance and IFU claims are still valid as science and clinical practice change. The PMPF Evaluation Report then summarizes and interprets the collected evidence and triggers updates to the Performance Evaluation Report (PER), risk management, labeling/IFU, or CAPA when needed.

PMS vs PMPF is easy to remember: PMS = broad safety/quality monitoring (often reactive), while PMPF = planned, proactive performance confirmation using structured sources like studies, registries, literature, or real-world datasets. PMPF can sometimes be justified as “not needed” for well-established devices, but this must be clearly documented and strongly supported because notified bodies usually expect a convincing rationale, not a simple statement.

Introduction

Post-Market Performance Follow-up (PMPF) is a continuous and proactive process defined under the In Vitro Diagnostic Regulation (EU) 2017/746 (IVDR). Its purpose is to ensure that an in-vitro diagnostic (IVD) device continues to meet its intended performance, safety, and clinical benefit throughout its lifecycle. Unlike a one-time evaluation at the time of CE-marking, PMPF keeps the performance evaluation alive, ensuring that real-world use and evolving clinical knowledge are continuously captured and acted upon. It complements the Post-Market Surveillance (PMS) system and feeds data into risk management, clinical evidence updates, and labeling changes.

Regulatory Basis for PMPF under IVDR

The IVDR provides clear and binding requirements for PMPF:

Article 56(6):
The performance evaluation and its documentation shall be updated throughout the life cycle of the device concerned with data obtained from implementation of the manufacturer’s PMPF plan in accordance with Part B of Annex XIII and the post-market surveillance plan referred to in Article 79.
Annex XIII, Part B, Section 5 :
Details the exact elements that must appear in a PMPF Plan and the PMPF Evaluation Report. It also clarifies the need for integration with risk management (Annex I) and the Performance Evaluation Report (PER).

The result is a structured and auditable process that is critical for passing notified body audits and retaining the CE mark.

Key Objectives of PMPF

A strong PMPF strategy addresses several key goals:

Confirm real-world performance: Verify that the IVD consistently delivers sensitivity, specificity, and reproducibility across diverse laboratory and clinical settings.
Detect new or evolving risks: Identify emerging issues such as reagent instability, matrix effects, or false positives/negatives that may not have been evident in pre-market studies.
Maintain benefit–risk balance: Ensure that the intended medical benefit continues to outweigh potential risks over time.
Validate product claims: Confirm that the claims in the Instructions for Use (IFU) and technical documentation remain valid as scientific knowledge and clinical practice evolve.
Refine technical parameters: Adjust analytical cut-off values, test algorithms, or sample handling instructions when necessary.

Reference: Annex XIII, Part B, Section 5 – 5.1(a to d).

PMPF Plan: What Should It Include ?

The Post-Market Performance Follow-up (PMPF) Plan is a critical component of the performance evaluation framework under the In Vitro Diagnostic Medical Devices Regulation (IVDR) 2017/746. It outlines the proactive strategies manufacturers must implement to monitor and validate their device’s safety and performance after CE marking and market release.

It explains how a manufacturer will proactively collect and evaluate safety, performance, and scientific data once an IVD device is on the market.

The PMPF plan must:

Confirm the device’s safety and performance during its entire lifetime.
Detects new or emerging risks and any limits in performance.
Ensure the benefit–risk balance and clinical evidence remain acceptable.
Identify possible systematic misuse of the device.

It should clearly describe:

The methods and procedures for data collection (general and specific).
The rationale for these methods.
Links to the Performance Evaluation Report and Risk Management File.
Specific objectives and a time-bound schedule for PMPF activities.
An evaluation of similar devices and the current state of the art.
References to common specifications, harmonized standards, and relevant guidance.

References: Annex XIII, Part B, Sections 5.1 and 5.2 (a to h)

PMPF Evaluation Report

The PMPF Evaluation Report is where all collected evidence is analyzed and interpreted. It must:

Be part of the Performance Evaluation Report (PER) and linked to the technical documentation.
Include trend analysis of new findings, adverse events, or performance deviations.
Support updates to risk management, IFU, or labeling when new hazards or clinical insights emerge.
Be updated periodically, aligning with PMS reports or when significant new data is available.

Reference: Annex XIII, Part B, Section 5.2.

PMPF vs General PMS: Clarifying the Difference

While Post-Market Performance Follow-up (PMPF) is technically a subset of the broader Post-Market Surveillance (PMS) system, it plays a specialized and proactive role under the IVDR (In Vitro Diagnostic Regulation). Understanding how PMPF differs from general PMS is crucial for compliance and strategic product lifecycle management.

Aspect	PMS (Post-Market Surveillance)	PMPF (Post-Market Performance Follow-up)
Purpose	Overall monitoring of device safety, quality, and regulatory compliance.	Specific to verifying ongoing clinical and analytical performance of the device.
Regulatory Role	Ensures the device continues to meet general safety and performance requirements (GSPRs) throughout its lifecycle.	Confirms the scientific validity, analytical performance, and clinical performance through new or updated evidence.
Nature	Often reactive, relying on post-market feedback, complaints, vigilance data, and customer inputs.	Designed to be proactive, involving structured data collection, real-world evidence, and post-market clinical performance studies.
Data sources	– Complaints – Incident reports – Vigilance notifications – Customer feedback – CAPA investigations	– Clinical performance studies – Disease registries – Scientific literature reviews – Epidemiological studies – Real-world evidence databases
Timing & Frequency	Ongoing, based on the occurrence of post-market events or updates.	Planned and scheduled as per the PMPF Plan, with clear timelines and objectives.
Documentation Outputs	PMS Plan and PMS Report / PSUR (depending on risk class).	PMPF Plan and PMPF Evaluation Report.
Key Outcome	Identification of safety issues, compliance gaps, or product quality concerns.	Confirmation of clinical benefit, risk control, and ongoing performance claims.

When Can PMPF Be Waived?

IVDR allows justified waivers, but these are the exception, not the rule. A manufacturer may argue that a PMPF study is not needed if:

The device technology is well established, with extensive clinical history.
There are no significant residual risks requiring new performance data.
Adequate real-world evidence already exists, such as published long-term studies or external quality control schemes.

Such justification must be clearly documented in the PMS Plan and the technical file (Annex XIII, Part B, Section 5.1(e)). Notified bodies will carefully review the reasoning.

Integrating PMPF into Your Compliance Strategy

To make PMPF work efficiently:

Synchronize timelines: Plan PMPF activities to match PMS and PER update cycles.
Define internal responsibilities: Assign teams or roles (regulatory, clinical, quality) for data collection, trend analysis, and reporting.
Document traceability: Ensure every activity, from study design to corrective actions, is referenced in the technical documentation.
Close the feedback loop: Feed PMPF findings back into design controls, labeling, and risk management for continuous product improvement.

Consequences of PMPF Non-Compliance

Failure to maintain a robust PMPF process can have serious regulatory and commercial consequences, such as:

Notified Body non-conformity and suspension or withdrawal of the CE certificate.
Regulatory enforcement actions, including product recalls or market withdrawal.
Reputational and financial impact, as undetected risks could lead to adverse incidents and loss of customer trust.

Sample PMPF Plan Template Structure

A PMPF Plan typically follows this structure:

Objectives – Define key performance parameters and safety goals.
Methodology – Describe the clinical or analytical methods to be used.
Data sources – Identify literature, registries, or real-world datasets.
Timelines – Specify data collection intervals and reporting frequency.
Evaluation metrics – Define acceptance criteria and statistical methods.
Risk management linkage – Describe how findings feed into the RMP and PER.

Conclusion

PMPF is not a one-off exercise, but a living, dynamic process. It ensures that IVD devices remain safe, effective, and scientifically current throughout their lifecycle. PMPF into risk management, performance evaluation, and product development, manufacturers not only meet IVDR obligations but also strengthen product quality and market confidence.

How We Can Help

At Morulaa Healthtech, we help IVD manufacturers meet the IVDR 2017/746 PMPF requirements by providing end-to-end regulatory support. Our team prepares comprehensive PMPF plans that comply with Article 56(6) and Annex XIII, designs data-collection strategies, and compiles PMPF evaluation reports that integrate seamlessly into the Performance Evaluation Report and technical documentation. We also ensure alignment with Post-Market Surveillance and risk management activities, offering guidance on scheduling, justifying waivers when appropriate, and maintaining complete traceability. With our expertise, manufacturers can confidently maintain CE certification, control regulatory risk, and keep their IVD devices safe and market-ready.